The reported statements, read against the company's own industry.
What stands out
Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
2.70BCNY
404.75M · vs all stocks (USD)
Updated Oct 21, 2026
Revenue (TTM)
273.47MCNY
40.97M · vs all stocks (USD)
Updated Oct 21, 2026
Profit Margin
-6.31%
vs Health Information Services peers
Updated Oct 21, 2026
Beta
0.6000x
vs all stocks
Updated Oct 21, 2026
52-Week Change
-6.25%
vs all stocks
Updated Oct 21, 2026
Market Capitalization
2.70BCNY
404.75M · vs all stocks (USD)
Updated Oct 21, 2026
Enterprise Value
2.07BCNY
309.40M · vs all stocks (USD)
Updated Oct 21, 2026
Price to Sales (TTM)
9.90x
vs Health Information Services peers
Updated Oct 21, 2026
Price to Book (MRQ)
2.49x
vs Health Information Services peers
Updated Oct 21, 2026
Enterprise to Revenue
7.55x
vs Health Information Services peers
Updated Oct 21, 2026
Enterprise to EBITDA
-85.34x
vs Health Information Services peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 87.84×.Updated Oct 21, 2026
Gross Margin
40.21%
vs Health Information Services peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 31.37%.Updated Oct 21, 2026
Profit Margin
-6.31%
vs Health Information Services peers
Updated Oct 21, 2026
Operating Margin
-5.27%
vs Health Information Services peers
Updated Oct 21, 2026
Return on Assets (TTM)
-1.63%
vs Health Information Services peers
Updated Oct 21, 2026
Return on Equity (TTM)
-1.78%
vs Health Information Services peers
Updated Oct 21, 2026
Revenue (TTM)
273.47MCNY
40.97M · vs all stocks (USD)
Updated Oct 21, 2026
Revenue per Share (TTM)
2.49CNYUpdated Oct 21, 2026
Quarterly Revenue Growth
32.50%
vs Health Information Services peers
Updated Oct 21, 2026
Gross Profit (TTM)
85.78MCNY
12.85M · vs all stocks (USD)
Updated Oct 21, 2026
EBITDA (TTM)
23.51MCNY
3.52M · vs all stocks (USD)
Updated Oct 21, 2026
Net Income (TTM)
-17.25MCNY
-2.58M · vs all stocks (USD)
Updated Oct 21, 2026
Quarterly Earnings Growth (YoY)
30.90%
vs Health Information Services peers
Updated Oct 21, 2026
Operating Cash Flow (TTM)
-36.55MCNY
-5.48M · vs all stocks (USD)
Updated Oct 21, 2026
Levered Free Cash Flow (TTM)
-32.66MCNY
-4.89M · vs all stocks (USD)
Updated Oct 21, 2026
Payout Ratio
1250.00%
vs Health Information Services peers
Updated Oct 21, 2026
Minority Interest (Equity)
331.00KCNYFY2025 · Dec 31, 2025
Revenue
254.08MCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
162.13MCNYFY2025 · Dec 31, 2025
Gross Profit
91.94MCNYFY2025 · Dec 31, 2025
Operating Income
-2.41MCNY
-361.52K · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-19.71MCNYFY2025 · Dec 31, 2025
Income Tax Expense
-3.02MCNYFY2025 · Dec 31, 2025
Net Income
-16.68MCNYFY2025 · Dec 31, 2025
EBIT
-19.51MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
23.51MCNYFY2025 · Dec 31, 2025
Research & Development
32.20MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
34.33MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
2.78MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
8.21MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
194.93KCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.1400CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.1400CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
105.64MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
105.64MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-16.68MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
1.89MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-88.26MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-92.10MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
509.75MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-16.68MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
-7.42MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-33.02MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-31.14MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-3.85MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-70.00MCNYFY2025 · Dec 31, 2025
Sale of Investments
53.46MCNYFY2025 · Dec 31, 2025
Other Investing Activity
8.71MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-11.67MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
160.10KCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-29.96KCNYFY2025 · Dec 31, 2025
Other Financing Charges
-1.54MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-1.41MCNYFY2025 · Dec 31, 2025
Shares Outstanding
104.20MSharesUpdated Oct 21, 2026
Float Shares
37.01MSharesUpdated Oct 21, 2026
% Held by Insiders
65.09%
vs all stocks
Updated Oct 21, 2026
% Held by Institutions
0.89%
vs all stocks
Updated Oct 21, 2026
Total Cash (MRQ)
646.66MCNY
96.87M · vs all stocks (USD)
Updated Oct 21, 2026
Total Cash per Share (MRQ)
6.21CNYUpdated Oct 21, 2026
Total Debt (MRQ)
7.03MCNY
1.05M · vs all stocks (USD)
Updated Oct 21, 2026
Total Debt to Equity (MRQ)
0.0065x
vs Health Information Services peers
Updated Oct 21, 2026
Current Ratio (MRQ)
6.95x
vs Health Information Services peers
Updated Oct 21, 2026
Book Value per Share (MRQ)
10.44CNYUpdated Oct 21, 2026
Total Assets
1.25BCNY
187.07M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.07BCNYFY2025 · Dec 31, 2025
Total Liabilities
157.92MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
176.25MCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
12.97MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
144.95MCNYFY2025 · Dec 31, 2025
Cash
659.75MCNYFY2025 · Dec 31, 2025
Cash Equivalents
31.66MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
691.41MCNYFY2025 · Dec 31, 2025
Accounts Receivable
215.30MCNYFY2025 · Dec 31, 2025
Inventory
115.60MCNYFY2025 · Dec 31, 2025
Accounts Payable
77.45MCNYFY2025 · Dec 31, 2025
Short-term Debt
2.42MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
6.28MCNYFY2025 · Dec 31, 2025
Long-term Debt
3.93MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
104.20MCNYFY2025 · Dec 31, 2025
Retained Earnings
138.71MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.09BCNY
163.41M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
20.31CNYUpdated Oct 21, 2026
52-Week High
35.27CNYUpdated Oct 21, 2026
52-Week Change
-6.25%
vs all stocks
Updated Oct 21, 2026
Beta
0.6000x
vs all stocks
Updated Oct 21, 2026
50-Day MA
26.79CNYUpdated Oct 21, 2026
200-Day MA
27.81CNYUpdated Oct 21, 2026
Avg 10-Day Volume
1.96MSharesUpdated Oct 21, 2026
Avg 30-Day Volume
1.95MSharesUpdated Oct 21, 2026
Diluted EPS (TTM)
-0.1700CNYUpdated Oct 21, 2026
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.33Receivables vs revenue divergence: 3.06
High gross margins eroded by operating costsNotable